에 대한 최신 뉴스 Taoping (NASDAQ:TAOP) 주식

Taoping

Taoping Inc is a provider of cloud-app technologies for smart city IoT platforms, digital advertising delivery, and other internet-based information distribution systems in China. Its operating segment includes Cloud-based Technology (CBT), Blockchain Technology (BT), and Traditional Information Technology (TIT). It generates maximum revenue from the CBT segment. CBT segment includes cloud-based products and services offered to customers in the private sector including new media, healthcare, education, and residential community management.

Taoping Inc

Acumen Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ABOS#NASDAQ">ABOS</a>) reported quarterly losses of $(0.48) per share which beat the analyst consensus estimate of $(0.54) by 11.11 percent. This is a 92 percent decrease over losses of $(0.25) per share from the same period last year.

Earnings

Earnings Beats

News

ABOS

Acumen Pharmaceuticals Q1 GAAP EPS $(0.48) Beats $(0.54) Estimate

Camtek (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CAMT#NASDAQ">CAMT</a>) reported quarterly earnings of $0.79 per share which beat the analyst consensus estimate of $0.77 by 2.6 percent. This is a 23.44 percent increase over earnings of $0.64 per share from the same period last year. The company reported quarterly sales of $118.60 million which missed the analyst consensus estimate of $119.28 million by 0.57 percent. This is a 22.14 percent increase over sales of $97.10 million the same period last year.

Earnings Misses

CAMT

Camtek Q1 Adj. EPS $0.79 Beats $0.77 Estimate, Sales $118.60M Miss $119.28M Estimate

Needham analyst Quinn Bolton reiterates MagnaChip Semiconductor (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MX#NYSE">MX</a>) with a Buy and maintains $6 price target.

Price Target

Reiteration

Analyst Ratings

Needham Reiterates Buy on MagnaChip Semiconductor, Maintains $6 Price Target

Full Year 2025 Financial Guidance
<figure class="table"> 
<table>
<tbody>
<tr>
<td colspan="1" rowspan="1">($ in millions, except per share amounts) (unaudited)</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">Full Year 2025</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Revenue</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">$1,710 - $1,734</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Adjusted EBITDA</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">$463 - $478</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Adjusted EPS</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">$2.21 - $2.51</td>
</tr>
</tbody>
</table>
</figure>
 &nbsp;

Guidance

PSFE

Paysafe Affirms FY2025 Adj EPS Guidance Of $2.21-$2.51 Vs $2.95 Est; Narrows FY2025 Sales Guidance Of $1.71B-$1.73B Vs $1.83B Est

Barclays analyst Julian Mitchell upgrades Stanley Black &amp; Decker (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SWK#NYSE">SWK</a>) from Equal-Weight to Overweight and raises the price target from $69 to $90.

Upgrades

Barclays Upgrades Stanley Black & Decker to Overweight, Raises Price Target to $90

Under Armour (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UAA#NYSE">UAA</a>) reported quarterly losses of $(0.08) per share which met the analyst consensus estimate. This is a 172.73 percent decrease over earnings of $0.11 per share from the same period last year. The company reported quarterly sales of $1.18 billion which beat the analyst consensus estimate of $1.16 billion by 1.47 percent. This is a 11.34 percent decrease over sales of $1.33 billion the same period last year.

Under Armour Q4 Adj. EPS $(0.08), Inline, Sales $1.18B Beat $1.16B Estimate

Paysafe (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PSFE#NYSE">PSFE</a>) reported quarterly earnings of $0.34 per share which missed the analyst consensus estimate of $0.41 by 17.07 percent. This is a 40.35 percent decrease over earnings of $0.57 per share from the same period last year. The company reported quarterly sales of $401.00 million which missed the analyst consensus estimate of $404.56 million by 0.88 percent. This is a 4.01 percent decrease over sales of $417.74 million the same period last year.

Paysafe Q1 Adj. EPS $0.34 Misses $0.41 Estimate, Sales $401.00M Miss $404.56M Estimate

HC Wainwright &amp; Co. analyst Swayampakula Ramakanth reiterates Dianthus Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DNTH#NASDAQ">DNTH</a>) with a Buy and maintains $40 price target.

DNTH

HC Wainwright & Co. Reiterates Buy on Dianthus Therapeutics, Maintains $40 Price Target

Under Armour (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UA#NYSE">UA</a>) reported quarterly losses of $(0.08) per share which met the analyst consensus estimate. This is a 172.73 percent decrease over earnings of $0.11 per share from the same period last year. The company reported quarterly sales of $1.18 billion which beat the analyst consensus estimate of $1.17 billion by 1.23 percent. This is a 11.34 percent decrease over sales of $1.33 billion the same period last year.

Under Armour Q4 Adj. EPS $(0.08), Inline, Sales $1.18B Beat $1.17B Estimate

Endeavour Silver (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EXK#NYSE">EXK</a>) reported quarterly sales of $63.50 million which beat the analyst consensus estimate of $62.80 million by 1.11 percent. This is a 0.35 percent decrease over sales of $63.73 million the same period last year.

Endeavour Silver Q1 Sales $63.50M Beat $62.80M Estimate

Leerink Partners analyst Daina Graybosch downgrades Affimed (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AFMD#NASDAQ">AFMD</a>) from Outperform to Market Perform and lowers the price target from $5 to $0.39.

Downgrades

AFMD

Leerink Partners Downgrades Affimed to Market Perform, Lowers Price Target to $0.39

Better Home &amp; Finance (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BETR#NASDAQ">BETR</a>) reported $32.55 million in sales this quarter. This is a 46.30 percent increase over sales of $22.25 million the same period last year.

BETR

Better Home & Finance Q1 Sales $32.55M Up From $22.25M YoY, Adj. Net loss $46.18M Down From $42.83M YoY

Benchmark analyst Cody Acree maintains Indie Semiconductor (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INDI#NASDAQ">INDI</a>) with a Buy and lowers the price target from $8 to $6.

INDI

Benchmark Maintains Buy on Indie Semiconductor, Lowers Price Target to $6

<ul>
<li>New and updated data for MK-1084, an investigational KRAS G12C inhibitor, from the colorectal cancer and non-small cell lung cancer cohorts of the Phase 1 KANDLELIT-001 study will be presented</li>
<li>Zilovertamab vedotin and sacituzumab tirumotecan data to highlight progress in Merck's pipeline of innovative antibody-drug conjugates</li>
<li>Follow-up data for KEYTRUDA&#xAE; (pembrolizumab) and WELIREG&#xAE; (belzutifan), as well as new and updated analyses for KEYTRUDA in earlier stages of cancer, add to the body of evidence supporting the role of these medicines</li>
</ul>

Merck Highlights MK-1084 Data From KANDLELIT-001 in KRAS G12C-Mutated Colorectal And Lung Cancers At ASCO 2025

Full Year 2025 Outlook and Guidance Policy Given lower U.S. multi-state jackpot activity and the current worsening macroeconomic environment, the Company now expects revenue of approximately $2.55 billion and Adjusted EBITDA of approximately $1.10 billion, which align with the low end of the original ranges provided in February 2025; cash from operations is now expected to be a use of approximately $350 million, primarily to account for the incremental FX impact on the first two installments of the Italy Lotto license fee.
The Company provides guidance of select information related to its financial and operating performance, and such measures may differ from year to year. The guidance is only an estimate of what the Company believes is realizable as of the date of this release. Actual results will vary from the guidance and the variations may be material. The Company undertakes no intent or obligation to publicly update or revise any of these projections, whether as a result of new information, future events or otherwise, except as required by law.

Intl Game Tech Narrows FY2025 Sales Guidance from $2.55B-$2.65B to $2.55B vs $2.57B Est

Jefferies analyst Kelly Shi initiates coverage on Insmed (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INSM#NASDAQ">INSM</a>) with a Buy rating and announces Price Target of $105.

Initiation

INSM

Jefferies Initiates Coverage On Insmed with Buy Rating, Announces Price Target of $105

Intl Game Tech (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IGT#NYSE">IGT</a>) reported quarterly earnings of $0.09 per share which missed the analyst consensus estimate of $0.11 by 18.18 percent. This is a 67.86 percent decrease over earnings of $0.28 per share from the same period last year. The company reported quarterly sales of $583.00 million which missed the analyst consensus estimate of $627.84 million by 7.14 percent. This is a 11.80 percent decrease over sales of $661.00 million the same period last year.

Intl Game Tech Q1 Adj. EPS $0.09 Misses $0.11 Estimate, Sales $583.00M Miss $627.84M Estimate

Needham analyst Ryan Koontz reiterates Rocket Lab USA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RKLB#NASDAQ">RKLB</a>) with a Buy and maintains $28 price target.

RKLB

Needham Reiterates Buy on Rocket Lab USA, Maintains $28 Price Target

CNCK

Coincheck Group Q1 Sales $764.00M Up From $676.00M YoY, Net Profit $4.3M Down From $13M YoY

DA Davidson analyst Rudy Kessinger downgrades Rapid7 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RPD#NASDAQ">RPD</a>) from Neutral to Underperform and lowers the price target from $29 to $21.

DA Davidson Downgrades Rapid7 to Underperform, Lowers Price Target to $21

Press Releases

Taoping Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency

Contracts

AI-based Business Drives 32% Growth in Taoping's First Half 2024 Total Contract Revenue Value

Taoping Accelerates AI Business Growth with New Order for AI-Powered Smart Terminals

Alert: 30% YoY Growth in Taoping's July 2024 Total Contract Revenue Value Driven by Strong Demand for AI-Based Products

Taoping Reports 28.4% Increase in Revenue for the First Six Months of 2024, with EPS of $0.13 Per Diluted Share Compared to a Loss of $1.10 in the Corresponding Period of 2023

Taoping Signs Non-binding Letter of Intent to Acquire Yunti; Transformational Acquisition Would Substantially Improve Taoping's Annual Revenue, Expand its Addressable Market, and Leverage its Current Portfolio

Comments

Taoping

뉴스

에 대한 최신 뉴스 Taoping (NASDAQ:TAOP) 주식

사람들이 또한 지켜본다

뉴스

파트너 / 기고자

벤징가 글로벌